The year in gout: 2011-2012

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue 3, 2012, Pages 145-151

  Crittenden, Daria B ^a,b   Pillinger, Michael H ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CANAKINUMAB; COLCHICINE; DILTIAZEM; FEBUXOSTAT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; PEGLOTICASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; URIC ACID; VERAPAMIL;

COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DIET THERAPY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPIDEMIC; GOUT; HUMAN; HYPERURICEMIA; INFLAMMATION; INFUSION RELATED REACTION; MEDICAL RESEARCH; MORBIDITY; MORTALITY; OSTEOARTHRITIS; PREVALENCE; REVIEW; TREATMENT RESPONSE;

ANIMALS; COMORBIDITY; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; OSTEOARTHRITIS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84869397044     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41.
2. Kuo CF, Yu KH, See LC, et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine. 2011 Dec;78(6):577-80.
3. Wu EQ, Forsythe A, Guerin A, Yu AP, et al. Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. Am J Ther. 2011 Feb 10. [Epub ahead of print]
4. Edwards NL, Sundy JS, Forsythe A, et al. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10-5.
5. Chen YH, Hsieh SC, Chen WY, et al. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFbeta1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann Rheum Dis. 2011 Sep;70(9):1655-63
6. Mitroulis I, Kambas K, Chrysanthopoulou A, et al. Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gout. PLoS One. 2011;6(12):e29318.
7. Chhana A, Callon KE, Pool B, et al. Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann Rheum Dis. 2011 Sep;70(9):1684-91.
8. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011 Feb;124(2):155-63.
9. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012 Feb 15;2(1):e000282.
10. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012 Jul;125(7):679-87 e1.
11. Chen J-H, Pan W-H. Effects of urate lowering therapy on cardiovascular mortality: a Taiwanese cohort study. Arthritis Rheum. 2010;62:S872-3(2008).
12. Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012 Jul;39(7):1458-64.
13. Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011 Jan;17(1):7-13.
14. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011 Aug;6(8):1887-94.
15. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardio-vascular risk. Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93.
16. Denoble AE, Huffman KM, Stabler TV, et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2088-93.
17. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001 Feb;13(1):114-9.
18. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003 Oct 2;425(6957):516-21.
19. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9;440(7081):237-41.
20. Muehleman C, Li J, Aigner T, et al. Association between crystals and cartilage degeneration in the ankle. J Rheumatol. 2008 Jun;35(6):1108-17.
21. Aran S, Malekzadeh S, Seifirad S. A double-blind randomized controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee. Clin Exp Rheumatol. 2011 May-Jun;29(3):513-8.
22. Choi HK, Al-Arfaj AM, Eftekhari A, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2009 Oct;68(10):1609-12.
23. Manger B, Lell M, Wacker J, et al. Detection of periarticular urate deposits with dual energy CT in patients with acute gouty arthritis. Ann Rheum Dis. 2012 Mar;71(3):470-2.
24. Bongartz T, Glazebrook KN, Kavros SJ, et al. Diagnosis of Gout Using Dual-Energy Computed Tomography: An Accuracy and Diagnostic Yield Study. Arthritis Rheum. 2011;63(10 Suppl):S77.
25. Choi HK, Burns LC, Shojania K, et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis. 2012 Sep;71(9):1466-71.
26. McQueen FM, Doyle A, Dalbeth N. Imaging in gout-what can we learn from MRI, CT, DECT and US? Arthritis Res Ther. 2011;13(6):246.
27. Howard RG, Pillinger MH, Gyftopoulos S, et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res (Hoboken). 2011 Oct;63(10):1456-62.
28. Li S, Micheletti R. Role of diet in rheumatic disease. Rheum Dis Clin North Am. 2011 Feb;37(1):119-33.
29. Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis. 2012 Sep;71(9):1448-53.
30. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005 Jan;52(1):283-9.
31. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008 Feb 9;336(7639):309-12.
32. White JS. Fructose as a significant cause of gout is unfounded and premature. QJM. 2012 Aug;105(8):809-10.
33. Dalbeth N, Palmano K. Effects of dairy intake on hyperuricemia and gout. Curr Rheumatol Rep. 2011 Apr;13(2):132-7.
34. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004 Mar 11;350(11):1093-103.
35. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj J. 2004;19(7-9):491-8.
36. Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010 Sep;69(9):1677-82.
37. Dalbeth N, Gracey E, Pool B, et al. Identification of dairy fractions with anti-inflammatory properties in models of acute gout. Ann Rheum Dis. 2010 Apr;69(4):766-9.
38. Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-ofconcept randomised controlled trial. Ann Rheum Dis. 2012 Jun;71(6):929-34.
39. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr;62(4):1060-8.
40. Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidencebased colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug;63(8):2226-37.
41. Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011 Mar 25;13(2):R53.
42. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012 May 14. [Epub ahead of print].
43. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study. Ann Rheum Dis. 2011 Jul;70(7):1264-71.
44. Schumacher HR, Jr., Evans RR, Saag KG, et al. Rilonacept (Interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results of the presurge-1 trial. Arthritis Care Res (Hoboken). 2012 May 1. [Epub ahead of print].
45. Schumacher HR, Jr., Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012 Mar;64(3):876-84.
46. Abeles AM. The need to compare rilonacept against active treatment for prevention of gout flares: comment on the article by Schumacher et al. Arthritis Rheum. 2012 Jul;64(7):2415-6; author reply 2416.
47. Pandya BJ, Pinsky BW, Rey GG, Singh JA. Serum urate lowering effectiveness of febuxostat compared with allopurinol and switching to febuxostat from allopurinol in the real world setting. Arthritis Rheum. 2011;63(Suppl 10):891.
48. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17;306(7):711-20.